Adlai Nortye closed fiscal 2025 with a $35.5 million net loss on a one-time revenue line, just $8.1 million of unrestricted cash, and a stockholders' deficit of $8.3 million after two consecutive years of operating losses. Six months later, the same balance sheet sits inside a different story: a $140 million PIPE financing closed in two tranches during February and April 2026, an exclusive China license with Jiangsu Aosaikang Pharmaceutical that carries up to roughly $230 million (RMB 1.6 billion) in milestone payments, and a five-asset oncology pipeline whose first clinical readouts now have quarters attached. The stock trades at $13.09 per ADS following a round trip from a $0.88 low in December 2025 (when the cash ran out) to a $17.25 high in April 2026 (when the PIPE priced) - a roughly fifteen-fold move that has now settled to a market capitalization near $954 million on a $157 million post-financing cash base, for an enterprise value of roughly $820 million against zero recurring revenue and a fiscal-year loss that was the smallest of the three years on the income statement. The thesis the market is paying for is a clinical milestone calendar, not a current P&L, and the report's job is to identify which of the five readout clocks actually binds the next twelve months of equity value.
The pipeline carries the story. The two most advanced assets - AN9025, an oral pan-RAS(ON) inhibitor, and AN8025, a tri-functional PD-L1/CD86v/LAG3v fusion protein - are both in Phase 1, with the AN9025 first-patient-dosed announcement landing February 12, 2026, and a global Phase 1 trial of AN4035 (a CEACAM5-targeting pan-RAS(ON) inhibitor ADC) cleared to start in Australia on August 3, 2026. AN4005 is in expansion phase for an oral PD-L1 inhibitor with proof-of-concept data expected in the second half of 2026, and AN0025, the in-licensed EP4 antagonist, cleared its futility analysis in March 2026 with topline Phase 2 results due in the first half of 2027. Each of those five events is binary, dated, and the kind of catalyst a small-cap oncology market can reprice in a day. The current $13.09 ADS price is the market's own discount on whether those readouts will land - and on whether the $157 million of pro forma cash survives the burn long enough for any of them to register.
Three forces bound the equity over the next twelve months. First, clinical execution: AN9025 Phase 1 dose escalation data, AN4005 expansion-phase proof-of-concept, AN0025 Phase 2 topline, and the AN4035 IND filing all fall in 2026 and early 2027. Second, cash discipline: pro forma cash of roughly $157 million against an annualized operating burn near the FY2025 rate of $33 million a year gives an explicit runway of roughly 4.5 years before the next financing, longer than any of the dated readouts. Third, the HFCAA overhang: as a Cayman-incorporated company whose primary operating subsidiary is in mainland China, Adlai Nortye remains subject to the U.S. Holding Foreign Companies Accountable Act and PCAOB-inspection requirements, and the auditors' report on FY2025 is from BDO China Shu Lun Pan - a name on the PCAOB's inspectable list. The 20-F is clean, the auditors are inspectable, but the regulatory pathway is the only one of the three forces entirely outside management's control.